Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

X
Trial Profile

Safety and efficacy of orally administered Fx-1006A in patients with familial amyloid polyneuropathy (FAP): A randomized, double-blind, placebo-controlled study.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Familial amyloid neuropathy
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Aug 2016 According to a Pfizer media release, results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) were published online in Amyloid: The Journal of Protein Folding Disorders.
    • 08 Aug 2016 Results of pooled post hoc analysis from this and other two trials (Profiles 275556 and 252196) published in a Pfizer media release.
    • 23 Jun 2015 Post hoc analysis (supporting tafamidis for delaying progression) results presented at the 1st Congress of the European Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top